Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

Abstract The RxPONDER and TAILORx trials demonstrated benefit from adjuvant chemotherapy in patients age ≤ 50 with node-positive breast cancer and Recurrence Score (RS) 0–26, and in node-negative disease with RS 16–25, respectively, but no benefit in older women with the same clinical features. We a...

Full description

Bibliographic Details
Main Authors: Tao Qing, Thomas Karn, Mariya Rozenblit, Julia Foldi, Michal Marczyk, Naing Lin Shan, Kim Blenman, Uwe Holtrich, Kevin Kalinsky, Funda Meric-Bernstam, Lajos Pusztai
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00492-0

Internet

https://doi.org/10.1038/s41523-022-00492-0

Similar Items